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Abstract
Williams–Beuren syndrome (WBS) is a neurodevelopmental and multisystemic disease that
results from hemizygosity of approximately 25 genes mapping to chromosomal region 7q11.23.
We report here the preliminary description of eight novel genes mapping within the WBS critical
region and/or its syntenic mouse region. Three of these genes, TRIM50, TRIM73 and TRIM74,
belong to the TRIpartite motif gene family, members of which were shown to be associated to
several human genetic diseases. We describe the preliminary functional characterization of these
genes and show that Trim50 encodes an E3 ubiquitin ligase, opening the interesting hypothesis
that the ubiquitin-mediated proteasome pathway might be involved in the WBS phenotype.
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Introduction
The Williams–Beuren syndrome (OMIM#194050) is characterized by mental retardation
with unique cognitive and personality profile and multiple dysmorphic and metabolic
features.1-5 WBS is caused by a microdeletion of a 1.55 or 1.84 Mb region mapping to
chromosome band 7q11.23,6 that contains about two dozen of genes.7-11 The hemizygosity
of this region is almost exclusively due to sporadic de novo deletions.1,3,12 Mouse models
of LIMK1, CYLN2 and GTF2IRD1 suggest that hemizygosity of these genes might play a
role in some aspects of this phenotype and/or in craniofacial anomalies13-15 although no
absolute association was established. On the contrary, the hemizygosity of the ELN gene
was unequivocally linked to the supravalvular aortic stenosis phenotype.16 Further
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genotype–phenotype correlations have been proposed following diagnosis of atypical
patients presenting smaller or ‘shifted’ deletions.13,17-26 Nevertheless further
understanding of the molecular pathogenesis of WBS requires the identification and
functional characterization of all the genes mapping within the 7q11.23 WBS region.
The TRIpartite motif (TRIM) proteins (also known as RBCC proteins) harbor from their N-
to their C-terminal end, a RING (R), one or two B-boxes (B) and a predicted Coiled coil
(CC).27-30 The TRIM motif is usually followed by either one or two C-terminal domains,
which are specific for each member of the family. To date, more than 68 genes encoding
TRIM proteins have been identified in the human genome.31 Alteration of these proteins
causes pathological conditions that range from Mendelian diseases to cancer development
and viral infection.32-40 In this study, we report the preliminary description of eight
mammalian genes mapping in the WBS critical region (WBSCR) and/or the mouse syntenic
5G1 band and experimental evidence showing that one of those genes, TRIM50 encodes an
E3 ubiquitin ligase.
Materials and methods
Gene identification and cDNAs
A fully detailed description of the procedure followed for gene identification and sequencing
can be viewed in the Supplementary online section. Briefly, we screened the human and
mouse dbEST databases to create clusters of ESTs mapping to the genomic interval of
interest. These contigs were repeatedly extended by rescreening of dbEST until no new
matching ESTs were found.41,42 To identify the 5′-end of the TRIM50-like genes 5′-rapid
amplification of cDNA ends was performed on polyA+ RNAs from 12 human tissues as
described.43
Northern blot
Mouse northern RNA blot-12 major tissues (Origene) were hybridized following the
manufacturers' recommendations with the inserts of IMAGE clones 3484221 (Wbscr24),
602660 (Wbscr25), 336334 (Wbscr26), 4950109 (Wbscr27), with the 1452 bp Trim50 ORF
fragment, or with the 464 bp Wbscr28 partial ORF fragment. Sample loading was assessed
using an actin probe (not shown).
Fusion plasmids
The full-length ORF of mouse Trim50 was cloned into pCDNA3 vectors modified to
include either an myc-EGFP or an HA-tag.30 Trim50 deletion mutants were created using
appropriate oligonucleotides and amplification followed by in-frame insertion into the above
vectors. The Trim50 A251X that correspond to a murine Trim73-like cDNA was engineered
with the Quick-change directed mutagenesis kit (Stratagene).
Cell culture and transfection
293T, COS-7, HeLa, U2OS and HepG2 cells (ATCC) were maintained in Dulbecco's
modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum and 1%
antibiotics. Fugene 6 (Roche) was used for transfection according to the manufacturers'
instructions.
Immunoprecipitation and western blot
Co-immunoprecipitation experiments were performed as described previously.44,45
Complexes were analyzed by western blotting using appropriate antibodies (anti-GFP and
anti-myc (Santa Cruz Biotechnology), anti-HA (Covance) and anti-FLAG (Sigma).
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Horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies (GE Healthcare)
and the ECL chemiluminescence system (GE Healthcare) were used for detection. Where
indicated, the MG132 proteasome inhibitor (Santa Cruz Biotechnology) was added at 10 μM
for 4 h.
Interaction mating
Interaction mating is a variation of the classic two-hybrid screening. The bait plasmids
express the cDNA directionally fused to the first 202 residues of LexA under the control of
the constitutive ADH promoter. Prey plasmids express cDNAs fused to the B42 activation
domain, the SV40 T nuclear localization signal (NLS) and an HA tag under the control of
the inducible GAL1 promoter. The two plasmids are introduced separately in the two yeast
haploid strains EGY48 and EGY42. The pSH18-34 vector with 6 LexA-operators lacZ and a
genome integrated 4 LexA-operators LEU2 are used as reporters. EGY48/EGY42 diploids
for every pairwise combination were generated by mating.46
Cross-linking and turnover rate assay
Lysates of U20S cells transfected with myc-EGFP-Trim50 were incubated with varying
concentrations (0, 0.2, 0.4, 0.8, 2.0 mM) of glutaraldehyde (Sigma) at room temperature for 5
min, followed by the addition of an excess of glycine to quench the reaction. The cross-
linked lysates were then subjected to western blot using anti-GFP antibody. Transfected
U20S with myc-EGFP-Trim50 were treated with 100 μg/ml of cycloheximide at different
time points and cell lysates containing equal amount of total proteins were subjected to
western blot using anti-GFP and GAPDH antibodies.
Subcellular localization
Transfected cells were fixed in 4% formaldehyde for 15 min at room temperature, washed,
permeabilized with 0.1% Triton X-100 and blocked 1 h with 1% bovine serum albumin. The
anti-HA antibody (Covance) and the secondary anti-mouse AlexaFluor 568 (Molecular
Probes) were used at 1:1000 and 1:500 dilutions, respectively. Cells were incubated for 1 h
with the primary antibody at room temperature. After extensive washing, cells were
incubated with the secondary antibody for 1 h at room temperature. Nuclei were stained with
DAPI (0.5 μg/ml). MitoTracker, ER-Tracker, LysoTracker and SelectFX 488 Peroxisome
Labeling Kit (all Molecular Probes) and ADLP (Chemicon) were used for staining of
mitochondria, endoplasmic reticulum, lysosomes, PMP70 and ADLP peroxisomal proteins,
respectively.
Results
Genes from the WBSCR
To refine the WBSCR annotation, we identified, cloned and sequenced the human
WBSCR24, WBSCR26, WBSCR27, WBSCR28, TRIM50, TRIM73 and TRIM74 genes and
the murine Wbscr24, Wbscr25, Wbscr26, Wbscr27, Wbscr28 and Trim50 genes
(nomenclature committee approved symbols, ie, WBSCR transcript 24–28, TRIM gene 50,
73 and 74). A schematic representation of the region is depicted in Figure 1. All sequences
were deposited in GenBank (AF498998–999, AK008014, AY081947–954, AY352519,
AY354925–928, AY369079-080, AY372053–054 and BM008899). Mouse tissue northern
blots were performed to confirm these as bona fide genes (Figure 2). The size of the
Wbscr24-, Wbscr25-, Wbscr26-, Wbscr27- and Wbscr28-deposited sequences is analogous
to the estimated sizes determined by northern blotting for these transcripts, suggesting that
we have identified and sequenced the entire mouse cDNAs (Supplementary Table S1), while
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we confirmed the entire Trim50 ORF by RT–PCR followed by sequencing (see ‘Materials
and methods’).
TRIM50, TRIM73 and TRIM74
We identified three TRIM50-like copies on the human genome, TRIM50 (also known as
TRIM50A), TRIM73 (TRIM50B) and TRIM74 (TRIM50C). All three are expressed, as
demonstrated by the identification of spliced ESTs specific to each transcript. TRIM50 maps
between WBSCR20A and FKBP6 within repeat BLOCK C-mid, TRIM73 between
WBSCR20B and FKBP6T2 in BLOCK C-tel, while TRIM74 maps to the BLOCK C-cen
interval, between WBSCR20C and FKBP6T1 (Figure 1).8,10,47 WBS patients are therefore
hemizygotes for TRIM50, but not for TRIM73 and TRIM74 (Figure 1).6 TRIM50, TRIM73
and TRIM74 share five orthologous exons. Stronger sequence conservation is observed
between the telomeric and centromeric TRIM50-like copies (TRIM73 and TRIM74,
947/949 bp identity (99.8%)), than between these copies and the central copy (TRIM50,
913/949 (96.2%) and 914/949 bp (96.3%) identity, respectively) (Figure 1). The sequences
of the three TRIM50-like copies diverge after exon 5, as exons 6 and 7 are absent from
BLOCK C-cen and BLOCK C-tel.
The TRIM50 transcript encodes a putative protein of 487 residues 88% identical to its
murine orthologue (Trim50). The presence of a single copy of TRIM50-like genes in rodents
is consistent with the absence of duplications in the WBS-corresponding region of mouse
chromosome 5.11,48 TRIM50 and Trim50 harbor, from their N- to their C-terminal end, a
RING, a B-box type 2, a CC and an RFP-like/B30.2 domain. TRIM73 and TRIM74 encode
almost identical putative proteins of 250 residues (99.6% identical, 249/250) containing only
the R, B2 and CC domains. These peptides are 93 (233/250) and 94% (234/250) identical to
the first 250 amino-acid residues encoded by TRIM50. They show 80% identity to Trim50
(201/250), in a region where TRIM50 and Trim50 are 85% identical (212/250), an
observation consistent with the notion that speciation preceded duplication.
Trim50 encodes an E3 ubiquitin ligase
Because recent data suggest that some TRIM proteins act as E3 ubiquitin ligase31,49-55 we
investigated whether Trim50 retains this ability. First, we co-transfected HEK293T cells
with HA-tagged Trim50 (HA-Trim50) and myc-tagged ubiquitin-expressing plasmids or
corresponding empty vectors. Total cell lysates were immunoprecipitated with anti-HA
antibody, separated by gel electrophoresis and subjected to western blot analysis with anti-
myc antibody (Figure 3a). The precipitated HA-Trim50 is polyubiquitinated at varying
degree. These polypeptides are detected as a high-molecular weight smear. Specificity of
this signal is assessed by transfection with the myc-tag vector only (compare lane 2 with
lane 1 and lane 4 with lane 8). The formation of the Trim50-Ub polypeptides is increased in
presence of UbcH8 (also known as UBE2L6), an E2 ubiquitin-conjugating enzyme
(compare lanes 3 and 2). Further intensification of the signal is achieved through
inactivation of the proteasome with the MG132 inhibitor (compare lanes 4 and 3). Similar
results were obtained using transfected COS-7 cells (data not shown).
E3 ubiquitin ligase enzymes directly interact with E2 ubiquitin-conjugating enzymes and
their substrate.56 To further assess the E3 ubiquitin ligase activity of Trim50, we therefore
investigated if this protein was able to interact with some E2 ubiquitin-conjugating enzymes.
We found that Trim50 preferentially binds to ubiquitin-conjugating enzyme UbcH8
(UBE2L6) rather than UbcH7 (UBE2L3; Figure 3b) in immunoprecipitation experiments.
Moreover, we took advantage of the yeast interaction-mating technology46 to determine if
Trim50 was able to bind to other E2 enzymes. The cDNAs encoding Trim50 and several E2
enzymes were expressed as fusion proteins with the LexA-DNA-binding domain (baits) and
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tested for interaction in a binary assay with the same proteins fused to the B42-acidic moiety
(preys). Strong binding was observed with UbcH6 (UBE2E1) and UbcH9 (UBE2E3; Figure
4a). Weak binding was detected with an additional E2 enzyme, UbcH5B (UBE2D2), while
no interaction was detected with UbcH2 (UBE2H) (data not shown). We then sought to
investigate whether, as reported for other RING-containing E3 ubiquitin ligases, the RING
domain of Trim50 was responsible of the specific interaction with the E2-conjugating
enzyme.57 To assess the contribution of each TRIM domain we created a set of Trim50
deletion mutants (Figure 4b) and tested their ability to retain the binding with the E2
ubiquitin-conjugating enzymes in interaction-mating and co-immunoprecipitation
experiments. We confirmed that the RING domain is necessary and sufficient for binding to
E2 enzymes (Figures 3c and 4a).
Together these results indicate that Trim50 is a novel E3 ubiquitin ligase that through the
RING domain catalyzes ubiquitination in presence of UbcH8 and possibly other E2s and
that Trim50 is itself ubiquitinated.
Trim50 is a stable protein that trimerizes
TRIM proteins were shown to define specific subcellular compartments as a consequence of
their propensity to form higher-order molecular weight structures and oligomerization seems
to be a common feature of cytoplasmic TRIM family members.30,58,59 To investigate
whether also Trim50 has this propensity, we first performed yeast interaction-mating assays
and showed that Trim50 is able to homodimerize (data not shown). In addition lysates from
U2OS cells transfected with myc-EGFP-Trim50 were incubated with increasing
concentration of glutaraldehyde and analyzed by western blotting. As reported in Figure 5a,
Trim50 is cross-linked into gel-stable complexes with high molecular weight of
approximately 250 kDa consistent with the formation of trimers.
Next, we examined the half-life of Trim50 in U20S-transfected cell lines treated with
cycloheximide and assayed for protein expression level at different points. These
experiments demonstrate that Trim50 is a stable protein also 6 h after treatment (Figure 5b).
Trim50 subcellular localization
We investigated the subcellular localization of Trim50 in mammalian cell lines. Ectopically
expressed Trim50 localizes into discrete cytoplasmic structures in COS-7, HeLa, HepG2 and
293T cells (Figure 6; data not shown). Next, we investigated the contribution of the TRIM
domains to this localization (Figures 4b and 6). Independent expression of the RING and the
RFP domain shows a diffuse nuclear and a vast perinuclear subcellular distribution,
respectively (Figures 6g and m), suggesting that these domains include an NLS and a
nuclear export signal, respectively. Consistently, deletion of the RFP domain induces
relocalization of the mutant protein to discrete nuclear structures, while the RING domain
deletion mutant localizes like the full-length protein (Figures 6j and p). The expression of a
construct carrying only the B-box and the CC domains defines the same discrete
cytoplasmic structures as the full-length and the RING domain-deleted protein (Figure 6s).
This construct also shows a weak diffuse signal in the nucleus, suggestive of a decreased
capacity of this protein to be exported outside of the nucleus. These results confirm that the
central region of the tripartite proteins (B-box and CC domains) is indispensable for the
proper localization to subcellular compartments,30 while the RING and RFP domains
cooperate to this localization.
Next, we compared the localization of myc-EGFP-Trim50 with compartment-specific
cellular markers. No co-localization of Trim50 staining was observed with endoplasmic
reticulum (Figures 7p–r), mitochondria (Figures 7m–o) and lysosomes (Figures 7g–i).
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Interestingly, we observed a partial colocalization with peroxisomes (Figures 7a–f and j–l).
These results are in agreement with the notion that TRIM proteins mainly define novel
subcellular compartments.30
Discussion
To identify candidate genes for the multiple WBS phenotypes and contribute to the update
of the WBSCR annotation, we analyzed ESTs and cDNAs corresponding to previously
identified.11 and novel transcription units. Our analysis allowed the mapping and
sequencing of eight mammalian genes mapping to 7q11.23 (WBSCR24, WBSCR26,
WBSCR27, WBSCR28, TRIM50, TRIM73, TRIM74) or the mouse syntenic 5G1 band
(Wbscr24, Wbscr25, Wbscr26, Wbscr27, Wbscr28, Trim50). They encode TRIM-containing
proteins (TRIM50, TRIM73, TRIM74 and Trim50), proteins containing a ‘modifier of
rudimentary’ (WBSCR24 and Wbscr24) or a methyltransferase domain (WBSCR27 and
Wbscr27). The role of these novel genes in the pathology of WBS remains to be determined;
however we present here the preliminary genomic and functional characterization of
Trim50.
Trim50 specifically interacts with E2 ubiquitin-conjugating enzymes and autoubiquitinates
showing that it can act as an E3 ubiquitin ligase. This enzymatic activity was already
reported for other TRIM protein members, namely TRIM5δ, TRIM18/MID1, TRIM23/
ARD1, TRIM25/Efp and TRIM32/HT2A, TRIM37 targeting the degradation of proteins
such as phosphatase 2A and 14-3-3σ,49-51,53-55 The interaction of Trim50 with the E2
enzymes is mediated by the RING domain as already reported for other RING-containing
proteins.54,55,57,60 This E3 enzyme localizes to cytoplasmic aggregates that do not
correspond to organelles such as the endoplasmic reticulum, mitochondria, lysosomes,
although a very partial localization was shown with peroxisomes (Figure 7). This
localization is dependent on the integrity of a central region that includes the B-box type 2
and the CC domains (Figure 6). Many other TRIM family proteins showed co-localization
with cytoplasmic aggregates similar to those observed for Trim50.30 For example, TRIM20/
pyrin, defective in familial Mediterranean fever, forms perinuclear aggregates when
transiently expressed in cell culture.61 Similarly aggregates were reported for TRIM37,
defective in mulibrey nanism,50 supporting the notion that their formation is a common
propensity of TRIM proteins.31 These structures, named aggresomes, are defined as
perinuclear regions where misfolded and aggregated proteins are sequestered for
proteasomal degradation.62 Hence, we can speculate that the TRIM E3 ubiquitin ligases
localize to these sites to control the ubiquitination and eventually the degradation of specific
targets.
WBS patients are hemizygous for TRIM50, but not for the paralogous TRIM73 and
TRIM74 copies (Figure 1)6 and the expression of this gene appears to be reduced
accordingly in lymphoblastoid cell lines established with patient blood.63
Thus hemizygosity of the TRIM50 E3 ubiquitin ligase possibly plays a role in the WBS
phenotype as the result of accumulation of specific TRIM50 target substrates.
Considering the myriad of substrates that can be targeted by an E3 ligase, it is not surprising
that mutations in these genes result in several pathological conditions. Consistently, several
syndromes associated with mental impairment such as Opitz syndrome (OMIM #300000),
mulibrey nanism (OMIM #253250), Bardet–Biedl syndrome (OMIM #209900) and limb-
girdle muscular dystrophy type 2H (OMIM #254110) are caused by mutations of TRIM
family E3 ubiquitin ligases.34-36,40 For example, TRIM18/MID1, the gene mutated in
Opitz syndrome, targets the catalytic subunit (PP2Ac) of the microtubule-associated
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phosphatase PP2A for degradation. Mutations in its B30.2 domain abolish microtubule
binding leading to accumulation of PP2Ac and hypophosphorylation of microtubule-
associated proteins.34,49
It is unclear how a defective TRIM50 E3 ligase activity could influence some of the clinical
manifestations of WBS. The specific expression of TRIM50 and Trim50 in stomach,
intestine, liver and brain (Figure 2; L Micale et al, unpublished data) suggest a possible
involvement of TRIM50 haploinsufficiency in the gastrointestinal pathologies and/or the
cognitive profile of WBS patients. The identification of TRIM50-interacting proteins, as
well as its substrates should provide a better understanding of the biological function of this
E3 ligase, as potentially an insight into the molecular pathogenesis of WBS.
It is likely, although not experimentally verified in this study, that both TRIM73 and
TRIM74 proteins retain their ability to act as E3 ligase because they have the CC and RING
domains. However, these proteins might not be fully redundant with TRIM50, because the
RFP-like domain (also known as B30.2), that is absent in TRIM73 and TRIM74, was
suggested to be important for interaction with proteasome subunits.64 Furthermore, our
Trim73-like construct, which mimics TRIM73 and TRIM74, also shows a nuclear staining
absent in Trim50 (Figure 4b; Supplementary Figure S1). Consistently, analysis of MID1
(TRIM18) mutations detected in Opitz syndrome patients demonstrated the importance of
the RFP-like domain in the proper localization of the protein.58,65
In conclusion, the present report increases the number of identified genes mapping within
the region commonly deleted in WBS patients and thus putatively involved in phenotype
determination. Having shown that one of these novel genes, TRIM50, acts as an E3
ubiquitin ligase opens the interesting hypothesis of a direct involvement of ubiquitination in
the WBS pathology.
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Figure 1.
Update of the schematic partial transcript map of the 7q11.23 region published by Bayes et
al6 with the results discussed in this report in normal chromosome (top) and in
chromosomes bearing the classical Williams–Beuren syndrome (WBS) deletions (1.55 and
1.84 Mb deletions, center and bottom, respectively). The different centromeric (c), middle
(m) and telomeric (t) duplicons within the low-copy repeats are represented by specific
arrows that specify their relative orientation and type (BLOCK A: yellow arrow (A);
BLOCK B: red arrow (B); BLOCK C: light blue arrow (C)). Transcript units are depicted by
dark blue rectangles and named above.
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Figure 2.
Northern blot analyses of mouse adult tissues probed with Trim50 (a), Wbscr24 (b),
Wbscr25 (c, d), Wbscr26 (e), Wbscr27 (f) and Wbscr28 (g, h). The 18 h exposures are
shown for Trim50, Wbscr24, Wbscr27 and Wbscr28, while both short (left column, 30 min)
and long (right column, 18 h) exposures are presented for Wbscr25 (c, d) and Wbscr28 (g,
h). Arrowheads on the right mark the position of the detected mRNAs. Bars on the left
indicate the position of the RNA size markers 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0 and 9.0
kb. Br, brain; He, heart; Ki, kidney; Li, liver; Lu, lung; Mu, muscle; Sk, skin; Si, small
intestine; Sp, spleen; St, stomach; Te, testis; Th, thymus.
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Figure 3.
Trim50 is a RING-finger-dependent E3 ubiquitin ligase. (a) The interaction between tagged
Trim50 and ubiquitin was assayed in transiently transfected 293T cells expressing the
indicated fusion proteins. Total cell lysates immunoprecipitated with anti-HA and
immunoblotted with anti-myc revealed several Trim50-ubiquitylated proteins (lanes 2–4).
(b) 293T cells co-transfected with EGFP-Trim50 and FLAG-tagged UbcH7 or UbcH8 were
immunoprecipitated with anti-GFP and detected with anti-FLAG. (c) 293T cells expressing
the indicated fusion proteins were immunoprecipitated with anti-GFP and revealed with
anti-FLAG.
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Figure 4.
Interaction-mating assays show that Trim50 interacts with E2 ubiquitin-conjugating
enzymes. (a) Bait strains containing plasmids that expressed LexA-fusions to E2 ubiquitin-
conjugating enzymes were mated to EGY48 derivatives that contained B42 fusions to
Trim50 and Trim50 deletion mutants. Plates contain either glucose (Glc) or galactose/
raffinose (Gal) and are devoid of leucine (L) or supplemented with X-Gal (X). The Trim50
deletion mutants used in (a) are schematically depicted and compared to full-length Trim50
in (b).
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Figure 5.
(a) Trim50 forms oligomers. Lysates of U2OS cells expressing myc-EGFP-tagged Trim50
and treated with the indicated amount of glutaraldehyde were separated on SDS–PAGE and
resolved by immunoblotting. TRIM6 was used as positive control. The position of the
molecular weight markers is indicated in kD on the right, while the single and double
asterisks mark the TRIM monomer and trimers, respectively. (b) Trim50 is a stable protein.
Lysates of U20S cells transfected with myc-EGFP-Trim50 were treated with cycloheximide
for a period of 6 h. Equal amounts of cell lysates were analyzed by immunoblotting with
anti-GFP (top) and anti-GAPDH as control (bottom).
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Figure 6.
Representative examples of subcellular localizations of exogenously expressed EGFP (a–c),
EGFP-TRIM50 full-length (d–f) and deletion mutants (g–u) in fixed DAPI-counterstained
COS-7 cultured cells, as visualized by indirect immunofluorescence analysis. Merged
images of the first two columns are presented in the third column (c–u). A schematic
representation of the Trim50 deletion mutants can be viewed in Figure 4a.
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Figure 7.
Distribution of exogenously expressed full-length tagged Trim50 and endogenous cell
compartments. HeLa cells transfected with HA-Trim50 (a, d) and counterstained with the
PMP70 peroxisomal marker (b, e) were fixed and analyzed 24 h (a–c) and 16 h (d–f) post
transfection. HepG2 cells transfected with EGFP-Trim50 (g, j, m, p) were counterstained
with the LYSO-tracker lysosomial marker (h), the ALDP peroxisomal marker (k), the
MITO-tracker mitochondrial marker (n) or the ER-tracker endoplasmic reticulum marker
(q) 16 h post transfection. Merged images of the first two columns are presented in the third
column (c–r).
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